免疫疗法
医学
溶瘤病毒
结直肠癌
癌症
黑色素瘤
免疫检查点
肺癌
肿瘤科
放射治疗
癌症研究
靶向治疗
化疗
嵌合抗原受体
癌症免疫疗法
免疫学
免疫系统
T细胞
抗原
肿瘤微环境
内科学
作者
Mei Feng,Zhongwei Zhao,Mengxuan Yang,Jiansong Ji,Di Zhu
标识
DOI:10.1016/j.canlet.2020.10.040
摘要
Colorectal cancer (CRC) is the leading cause of cancer death worldwide. CRC therapeutic strategies include surgical resection, chemotherapy, radiotherapy, and other approaches. However, patients with metastatic CRC have worse prognoses. In recent years, T-cell-based immunotherapy has elicited promising responses in B-cell malignancies, melanoma, and lung cancer, but most CRC patients are resistant to immunotherapy, chemotherapy, and targeted therapy. Immune checkpoint inhibitors have shown encouraging results in non-small cell lung cancer, melanoma, and other cancers, but immune checkpoint blockade is only effective for CRC subset with microsatellite instability. Other immunotherapies, such as cytokines, cancer vaccines, small molecules, oncolytic viruses, and chimeric antigen-receptor therapy, are currently in use against CRC. This review analyzes recent developments in immunotherapy for CRC treatment as well as the challenges in overcoming resistance.
科研通智能强力驱动
Strongly Powered by AbleSci AI